T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2333-2343

  Leisegang, Matthias ^a   Turqueti Neves, Adriana ^d   Engels, Boris ^a,e   Blankenstein, Thomas ^a,b   Schendel, Dolores J ^d   Uckert, Wolfgang ^a,c   Noessner, Elfriede ^d  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 2; MACROPHAGE INFLAMMATION PROTEIN 1BETA; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MOLECULAR CLONING; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE RECEPTOR GENE; TISSUE ENGINEERING; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA, RENAL CELL; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 77950991814     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2897     Document Type: Article

References (50)

1. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-776
2. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005;46:1-10.
3. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21: 233-240
4. Uckert W, Schumacher TN. TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol Immunother 2009;58:809-822
5. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129
6. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-546
7. Shablak A, Hawkins RE, Rothwell DG, Elkord E. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res 2009;15:6503-6510
8. Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 1997;20:416-418 (Pubitemid 27329580)
9. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998;352: 1691-1696
10. Reeves DJ, Liu CY. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2009;64:11-25.
11. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 1988; 48:206-214 (Pubitemid 18030352)
12. Finke JH, Rayman P, Alexander J, et al. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 1990;50:2363-2370 (Pubitemid 20134496)
13. Caignard A, Guillard M, Gaudin C, Escudier B, Triebel F, Dietrich PY. In situ demonstration of renal-cell-carcinoma-specific T-cell clones. Int J Cancer 1996;66:564-570
14. Gaugler B, Brouwenstijn N, Vantomme V, et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 1996;44:323-330 (Pubitemid 26293845)
15. Schendel DJ, Oberneder R, Falk CS, et al. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med 1997;75: 400-413 (Pubitemid 27297010)
16. Jantzer P, Schendel DJ. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 1998;58:3078-3086 (Pubitemid 28335090)
17. Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, Triebel F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol 1999;163:483-490 (Pubitemid 29295877)
18. Dorrschuck A, Schmidt A, Schnurer E, et al. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. Blood 2004;104:2591-2599 (Pubitemid 39331865)
19. Tykodi SS, Warren EH, Thompson JA, et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004;10:7799-7811
20. Geiger C, Nossner E, Frankenberger B, Falk CS, Pohla H, Schendel DJ. Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. J Mol Med 2009;87:595-612.
21. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-1476 (Pubitemid 46871329)
22. Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003;102: 3829-3836 (Pubitemid 37409408)
23. Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther 2005;16:799-810. (Pubitemid 40982329)
24. Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee HG. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 2007;56:117-128
25. Sato E, Torigoe T, Hirohashi Y, et al. Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res 2008;14:6916-6923
26. Takahashi Y, Harashima N, Kajigaya S, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 2008;118:1099-1109 (Pubitemid 351364617)
27. Wang QJ, Hanada K, Yang JC. Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas. J Immunol 2008;181:3769-3776
28. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000;7: 1063-1066 (Pubitemid 30398356)
29. Karttunen J, Sanderson S, Shastri N. Detection of rare antigenpresenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci U S A 1992;89:6020-6024
30. Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved α joining region. Blood 2003;102: 3530-3540 (Pubitemid 37409367)
31. Leisegang M, Engels B, Meyerhuber P, et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med 2008;86:573-583
32. Sommermeyer D, Neudorfer J, Weinhold M, et al. Designer T cells by T cell receptor replacement. Eur J Immunol 2006;36:3052-3059 (Pubitemid 44782577)
33. Schendel DJ, Gansbacher B, Oberneder R, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-4220
34. Steinle A, Reinhardt C, Jantzer P, Schendel DJ. In vivo expansion of HLA-B35 alloreactive T cells sharing homologous T cell receptors: evidence for maintenance of an oligoclonally dominated allospecificity by persistent stimulation with an autologous MHC/peptide complex. J Exp Med 1995;181:503-513
35. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995;42:455-500. (Pubitemid 26025063)
36. Engels B, Cam H, Schuler T, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 2003;14: 1155-1168 (Pubitemid 36930405)
37. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006;66:8878-8886 (Pubitemid 44449206)
38. Scholten KB, Kramer D, Kueter EW, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006;119:135-145
39. Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α. Gene Ther 2005;12:140-146 (Pubitemid 40185917)
40. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105. (Pubitemid 17196641)
41. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008;36: W503-8.
42. Wilde S, Sommermeyer D, Frankenberger B, et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 2009;114:2131-2139
43. Gerharz CD, Ramp U, Dejosez M, et al. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Lab Invest 1999; 79:1521-1534 (Pubitemid 30013917)
44. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1: 822-826
45. Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007;204:2473-2485 (Pubitemid 47529331)
46. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-258 (Pubitemid 351432801)
47. Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carcinomaassociated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999;59:5554-5559
48. Buchner A, Pohla H, Willimsky G, et al. Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma. Hum Gene Ther 2010;21: 285-297
49. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005;93:670-677 (Pubitemid 41486458)
50. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988;57:239-246 (Pubitemid 18096328)